Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.72 |
| ▸ | APP | P05067 | 2/20 | 0.65 |
| ▸ | RAD52 | P43351 | 6/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MERTK | Q12866 | 1/20 | 0.59 |
| ▸ | CASP6 | P55212 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23747980 | 1.00 | HTT (0.72) | HTTKDM4ETAAR1APPRAD52 | |
| SCHEMBL23747940 | 0.91 | HTT (0.69) | HTTKDM4ETAAR1APPRAD52 | |
| SCHEMBL2587104 | 0.90 | APP (0.76) | KDM4EAPPRAD52KMT2AMEN1 | |
| SCHEMBL23747981 | 0.87 | SLC2A1 (0.66) | HTTKDM4ETAAR1APPRAD52 | |
| SCHEMBL26645968 | 0.84 | TAAR1 (0.98) | HTTKDM4ETAAR1RAD52KMT2A | |
| SCHEMBL23748460 | 0.84 | RAD52 (0.77) | HTTKDM4ETAAR1APPRAD52 | |
| SCHEMBL30125093 | 0.83 | USP2 (0.58) | HTTKDM4ETAAR1APPRAD52 | |
| SCHEMBL23723460 | 0.83 | USP2 (0.58) | HTTKDM4ETAAR1APPRAD52 | |
| SCHEMBL22343385 | 0.81 | KMT2A (0.67) | HTTKDM4EAPPKMT2AMEN1 | |
| SCHEMBL29490079 | 0.81 | KMT2A (0.67) | HTTKDM4EAPPKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| EP-4100395-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | Trobio Therapeutics Pty Ltd (AU) | 2022-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | NQO2, TP53, ABL1 | HTT 3184/4885KDM4E 2051/4885TAAR1 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.